Nothing Special   »   [go: up one dir, main page]

DK0553244T4 - Målrettet immunostimulering med bispecifikke reagenser - Google Patents

Målrettet immunostimulering med bispecifikke reagenser

Info

Publication number
DK0553244T4
DK0553244T4 DK91919595T DK91919595T DK0553244T4 DK 0553244 T4 DK0553244 T4 DK 0553244T4 DK 91919595 T DK91919595 T DK 91919595T DK 91919595 T DK91919595 T DK 91919595T DK 0553244 T4 DK0553244 T4 DK 0553244T4
Authority
DK
Denmark
Prior art keywords
antigen
receptor
bispecific reagents
immunostimulation
targeted
Prior art date
Application number
DK91919595T
Other languages
English (en)
Other versions
DK0553244T3 (da
Inventor
Michael W Fanger
Jean Loup Romet-Lemonne
Original Assignee
Celldex Therapeutics Inc
Romet Lemonne Jean Loup
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24373308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0553244(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celldex Therapeutics Inc, Romet Lemonne Jean Loup filed Critical Celldex Therapeutics Inc
Publication of DK0553244T3 publication Critical patent/DK0553244T3/da
Application granted granted Critical
Publication of DK0553244T4 publication Critical patent/DK0553244T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
DK91919595T 1990-10-05 1991-10-04 Målrettet immunostimulering med bispecifikke reagenser DK0553244T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59308390A 1990-10-05 1990-10-05
PCT/US1991/007283 WO1992005793A1 (en) 1990-10-05 1991-10-04 Targeted immunostimulation with bispecific reagents

Publications (2)

Publication Number Publication Date
DK0553244T3 DK0553244T3 (da) 1999-08-30
DK0553244T4 true DK0553244T4 (da) 2005-08-01

Family

ID=24373308

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91919595T DK0553244T4 (da) 1990-10-05 1991-10-04 Målrettet immunostimulering med bispecifikke reagenser

Country Status (10)

Country Link
EP (1) EP0553244B8 (da)
JP (1) JP3583420B2 (da)
AT (1) ATE175118T1 (da)
AU (1) AU667460B2 (da)
CA (1) CA2093022C (da)
DE (1) DE69130709T3 (da)
DK (1) DK0553244T4 (da)
ES (1) ES2129029T5 (da)
GR (1) GR3029830T3 (da)
WO (1) WO1992005793A1 (da)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
AU5322494A (en) * 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
ATE218890T1 (de) * 1994-03-07 2002-06-15 Medarex Inc Bispezifische moleküle mit klinischer verwendbarkeit
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6365161B1 (en) 1995-06-07 2002-04-02 Medarex, Inc. Therapeutic compounds comprised of anti-FC receptor binding agents
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1997014426A1 (en) * 1995-10-20 1997-04-24 University Of Nebraska Board Of Regents Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
EP0808897A1 (en) * 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
AUPO280796A0 (en) * 1996-10-07 1996-10-31 Austin Research Institute, The Methods of activating or enhancing FC receptors
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
CA2311574A1 (en) 1997-12-02 1999-06-10 Medarex, Inc. Cells expressing anti-fc receptor binding components
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999050391A1 (en) * 1998-03-30 1999-10-07 I.D.M. Immuno-Designed Molecules Stimulated monocyte derived cells, their preparation and uses
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
DE19835633C1 (de) * 1998-08-06 1999-08-26 Gsf Forschungszentrum Umwelt Induktion einer Tumorimmunität durch Redirektion von Tumorzellen gegen Antigen-präsentierende Zellen
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
AU5867100A (en) * 1999-05-03 2000-12-12 Medarex, Inc. Human antibodies to staphylococcus aureus
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP2298355A3 (en) 2000-04-12 2011-06-29 Human Genome Sciences, Inc. Albumin fusion proteins
CA2408547A1 (en) 2000-05-11 2001-11-15 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
AU1994402A (en) 2000-11-28 2002-06-11 Mediummune Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
AU2002240197A1 (en) * 2001-02-01 2002-08-12 Tanox, Inc. Methods to generate and identify monoclonal antibodies to a large number of human antigens
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
HUP0303927A3 (en) 2001-04-24 2006-03-28 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and tnf-alpha
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
ATE427363T1 (de) 2002-01-08 2009-04-15 Novartis Vaccines & Diagnostic In kanzerísen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
EP1470161A1 (en) * 2002-01-18 2004-10-27 Inovio AS Bispecific antibody dna constructs for intramuscular administration
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
ES2391087T3 (es) 2003-04-11 2012-11-21 Medimmune, Llc Anticuerpos de IL-9 recombinantes y usos de los mismos
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
DK1729795T3 (da) 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin-fusionsproteiner
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
US7422966B2 (en) 2005-05-05 2008-09-09 Micron Technology, Inc. Technique for passivation of germanium
US7531637B2 (en) 2005-05-06 2009-05-12 Zymogenetics, Inc. IL-31 monoclonal antibodies
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
WO2007008604A2 (en) 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
JP2009502180A (ja) 2005-08-03 2009-01-29 アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド 多糖シンターゼ
DK2573114T3 (da) 2005-08-10 2016-07-04 Macrogenics Inc Identificering og fremstilling af antistoffer med en variant af Fc-regioner og fremgangsmåder til anvendelse af samme
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
KR101511787B1 (ko) 2005-11-04 2015-04-13 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
BRPI0618338A2 (pt) 2005-11-07 2011-08-23 Scripps Resarch Inst uso de inibidor de sinalização de fator tecidual, método para identificar um agente que inibe a sinalização de tf/viia, composições farmacêuticas e kit
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9056906B2 (en) 2006-06-14 2015-06-16 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CN101522713A (zh) 2006-09-01 2009-09-02 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
WO2008030735A2 (en) 2006-09-06 2008-03-13 Janssen Pharmaceutical N.V. Biomarkers for assessing response to c-met treatment
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP2099823B2 (en) 2006-12-01 2022-02-09 Seagen Inc. Variant target binding agents and uses thereof
AR064388A1 (es) 2006-12-18 2009-04-01 Genentech Inc Anticuerpos antagonistas anti- notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
AU2008205244B2 (en) 2007-01-09 2013-02-07 Biogen Ma Inc. Sp35 antibodies and uses thereof
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20100291073A1 (en) 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP4053546A1 (en) 2007-12-06 2022-09-07 Genalyte, Inc. Device and method for performing label-free monitoring of processes.
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
US9846126B2 (en) 2008-10-27 2017-12-19 Genalyte, Inc. Biosensors based on optical probing and sensing
CN118324847A (zh) 2008-10-29 2024-07-12 阿布林克斯公司 单域抗原结合性分子的纯化方法
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2356251A1 (en) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
ES2647823T3 (es) 2009-05-08 2017-12-26 Vaccinex, Inc. Anticuerpos anti-CD100 y métodos de uso de los mismos
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
EP2480573A1 (en) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
DK2483289T3 (da) 2009-10-02 2019-06-11 Biogen Ma Inc Fremgangsmåder til forebyggelse og fjernelse af trisulfidbindinger
DK2486141T3 (da) 2009-10-07 2018-04-23 Macrogenics Inc Fc-region-indeholdende polypeptider, der udviser forbedret effektor-funktion grundet ændringer af omfanget af fukosylering, og fremgangsmåder til deres anvendelse
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
CN106188284B (zh) 2010-07-09 2020-05-08 扬森疫苗与预防公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
CN103153328A (zh) 2010-07-16 2013-06-12 默克专利股份有限公司 肽在乳腺癌和/或骨转移灶的治疗中的用途
CA2810217C (en) 2010-09-02 2019-03-12 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
EP2614080A1 (en) 2010-09-10 2013-07-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
TWI545134B (zh) 2010-10-22 2016-08-11 西雅圖遺傳學公司 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效
EP3266881B1 (en) 2010-11-05 2019-12-25 Genalyte, Inc. Optical analyte detection systems and methods of use
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
CN103547592A (zh) 2011-03-30 2014-01-29 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
JP6236383B2 (ja) 2011-05-13 2017-11-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． トリスルフィド結合を防止および除去する方法
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
HUE056462T2 (hu) 2011-11-04 2022-02-28 Zymeworks Inc Stabil heterodimer antestest tervezés mutációkkal az FC domainben
EP2776022A1 (en) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
RU2014128467A (ru) 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
ES2725569T3 (es) 2012-02-10 2019-09-24 Seattle Genetics Inc Diagnóstico y tratamiento de cánceres que expresan CD30
IN2014DN08199A (da) 2012-03-02 2015-05-01 Vaccinex Inc
WO2013138251A1 (en) 2012-03-12 2013-09-19 The Board Of Trustes Of The University Of Illinois Optical analyte detection systems with magnetic enhancement and methods of use
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
MX362497B (es) 2012-05-15 2019-01-21 Eisai Inc Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
SG11201408330XA (en) 2012-05-24 2015-01-29 Mountgate Group Ltd Compositions and methods related to prevention and treatment of rabies infection
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
EP2869818A1 (en) 2012-07-06 2015-05-13 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
US20150376597A1 (en) 2013-02-08 2015-12-31 Friedrich Miescher Institute For Biomedical Research (Fmi) Novel methods for the targeted introduction of viruses into cells
US20160002325A1 (en) 2013-03-08 2016-01-07 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
US9983206B2 (en) 2013-03-15 2018-05-29 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
SG11201508681QA (en) 2013-05-06 2015-11-27 Scholar Rock Inc Compositions and methods for growth factor modulation
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
US10344319B2 (en) 2013-10-28 2019-07-09 Dots Technology Corp. Allergen detection
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
WO2015153916A1 (en) 2014-04-04 2015-10-08 Bionomics, Inc. Humanized antibodies that bind lgr5
WO2015159254A1 (en) 2014-04-16 2015-10-22 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
EP3154579A1 (en) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research New treatment against influenza virus
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
EP3157634B1 (en) 2014-06-23 2018-12-12 Bionomics, Inc. Antibodies that bind lgr4
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US10961298B2 (en) 2014-08-21 2021-03-30 The Government Of The United States, Represented By The Secretary Of The Army Monoclonal antibodies for treatment of microbial infections
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
US10485880B2 (en) 2014-12-15 2019-11-26 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
PT3277717T (pt) 2015-03-31 2021-02-01 Medimmune Ltd Uma nova forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
CA2990411A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
CN107921145A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物（adc）
EP3337822A1 (en) 2015-08-19 2018-06-27 Rutgers, The State University of New Jersey Novel methods of generating antibodies
EP3349791A1 (en) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3368566A1 (en) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w and biliary tract cancers
US11028181B2 (en) 2015-11-12 2021-06-08 Seagen Inc. Glycan-interacting compounds and methods of use
KR20220004226A (ko) 2016-03-22 2022-01-11 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US11447542B2 (en) 2016-08-05 2022-09-20 Medimmune, Llc Anti-O2 antibodies and uses thereof
WO2018049474A1 (en) 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
BR112019007147A2 (pt) 2016-10-19 2019-06-25 Humabs Biomed Sa anticorpos anti-o1 e usos dos mesmos
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
KR102628678B1 (ko) 2016-12-21 2024-01-25 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
BR112019018043A2 (pt) 2017-03-03 2020-04-07 Seattle Genetics Inc método de tratamento de câncer, e, conjugado de anticorpo-fármaco
CN110799529A (zh) 2017-04-22 2020-02-14 免疫治疗有限公司 改良lamp构建物
CN110913892A (zh) 2017-05-02 2020-03-24 免疫治疗有限公司 包含癌抗原的lamp(溶酶体相关膜蛋白)构建物
JP7366755B2 (ja) 2017-05-30 2023-10-23 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ 抗ダブルコルチン様キナーゼ１抗体および使用方法
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
WO2019035001A1 (en) 2017-08-18 2019-02-21 Friedrich Miescher Institute For Biomedical Research NEW METHODS FOR TARGETED INTRODUCTION OF VIRUSES IN CELLS AND TISSUES
MA50767A (fr) 2017-10-11 2020-08-19 Seattle Genetics Inc Procédés de réduction des effets secondaires d'une thérapie par conjugués de médicament anticorps anti-cd30
WO2019089870A1 (en) 2017-11-01 2019-05-09 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
JP2021502125A (ja) 2017-11-09 2021-01-28 ピンテオン セラピューティクス インコーポレイテッド ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
CN112040951A (zh) 2018-01-31 2020-12-04 拜耳股份公司 具有nampt抑制剂的抗体药物缀合物(adc)
TW202003047A (zh) 2018-03-23 2020-01-16 美商西雅圖遺傳學公司 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
EP3814379A4 (en) 2018-05-07 2022-03-30 Genmab A/S METHOD OF TREATMENT OF CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
CN112368020B (zh) 2018-05-07 2024-05-31 展马博联合股份有限公司 抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
EA202190059A1 (ru) 2018-06-18 2021-04-21 Байер Акциенгезельшафт Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности
NZ771700A (en) 2018-07-03 2024-07-05 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
WO2020072519A1 (en) 2018-10-01 2020-04-09 Seattle Genetics, Inc. Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
KR20210152472A (ko) 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 Cd22 항체 및 이를 사용하는 방법
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
US20220347313A1 (en) 2019-09-25 2022-11-03 Seagen, Inc. Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers
CA3155634A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
CN114641306A (zh) 2019-10-18 2022-06-17 免疫治疗有限公司 包含癌抗原的改良lamp构建物
AU2020379001A1 (en) 2019-11-04 2022-06-09 Paul RUBINSTEIN Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
BR112022008661A2 (pt) 2019-11-07 2022-07-19 Genmab As Método para tratar câncer em um sujeito, conjugado de anticorpo-fármaco que se liga ao fator de tecido, uso de um conjugado de anticorpo-fármaco, e, kit
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
JP2023512084A (ja) 2020-01-31 2023-03-23 シージェン インコーポレイテッド 抗ｃｄ３０抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用
US20230190949A1 (en) 2020-05-13 2023-06-22 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
CN116568337A (zh) 2020-08-04 2023-08-08 思进股份有限公司 抗cd228抗体和抗体-药物缀合物
JP2023540082A (ja) 2020-09-04 2023-09-21 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ＳＡＲＳ－ＣｏＶ－２ワクチン及び抗体
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
CA3200671A1 (en) 2020-11-17 2022-05-27 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
CA3200314A1 (en) 2020-12-01 2022-06-09 Peter Pavlik Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods
JP2024503657A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
AU2022293999A1 (en) 2021-06-14 2023-11-30 argenx BV Anti-il-9 antibodies and methods of use thereof
MX2023013915A (es) 2021-06-29 2024-01-25 Seagen Inc Métodos para tratar el cáncer con una combinación de un anticuerpo anti-cd70 no fucosilado y un antagonista de cd47.
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4413040A1 (en) 2021-10-06 2024-08-14 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
JP2024540017A (ja) 2021-10-29 2024-10-31 シージェン インコーポレイテッド 抗ｐｄ－１抗体と、抗ｃｄ３０抗体－薬物コンジュゲートとの組合せを用いてがんを処置する方法
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024097816A1 (en) 2022-11-03 2024-05-10 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
US20240226313A1 (en) 2022-11-17 2024-07-11 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024105205A1 (en) 2022-11-17 2024-05-23 Bayer Aktiengesellschaft Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
WO1991000360A1 (en) * 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy

Also Published As

Publication number Publication date
DK0553244T3 (da) 1999-08-30
EP0553244B2 (en) 2005-04-06
DE69130709T3 (de) 2005-12-22
CA2093022C (en) 2005-02-22
EP0553244A4 (da) 1994-02-09
ES2129029T3 (es) 1999-06-01
AU667460B2 (en) 1996-03-28
JPH06502410A (ja) 1994-03-17
WO1992005793A1 (en) 1992-04-16
AU8869491A (en) 1992-04-28
DE69130709T2 (de) 1999-07-22
CA2093022A1 (en) 1992-04-06
EP0553244A1 (en) 1993-08-04
EP0553244B8 (en) 2005-06-08
EP0553244B1 (en) 1998-12-30
JP3583420B2 (ja) 2004-11-04
GR3029830T3 (en) 1999-06-30
ATE175118T1 (de) 1999-01-15
ES2129029T5 (es) 2005-10-16
DE69130709D1 (de) 1999-02-11

Similar Documents

Publication Publication Date Title
DK0553244T3 (da) Målrettet immunostimulering med bispecifikke reagenser
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
FR2382460A1 (fr) Complexe antigene proteine pour bloquer les reactions allergiques
AU567723B2 (en) Binding proteins or antigens on polystyrene surface and its subsequent use in immuno assay
NL7705330A (nl) Werkwijze voor het vervaardigen van een elektro- magnetische inrichting alsmede inrichting ver- vaardigd door toepassing van de werkwijze.
NL7614579A (nl) Werkwijze voor het toepassen van silanen met ver- kapte functionele groepen als hechtmiddel.
DK0595798T3 (da) Bispecifikke heteroantistoffer med dobbelte effektorfunktioner
DE69504955D1 (de) Immunstimulierende monoklonale antikörper
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
FI914908A0 (fi) Ny monoklonal antikropp med ny antigen relaterad till humana tumoerer.
NO880705D0 (no) Fremgangsmaate til fremstilling av makromolekylare platinaforbindelser med virkning mot kreft.
NL7609225A (nl) Koppelingsorgaan voor veiligheidsgordels.
IT7830648A0 (it) Sedile imbottito con dispositivo di fissaggio particolarmente per cinture di sicurezza per autoveicoli.
IT7821489V0 (it) Dispositivo per il montaggio, in particolare di cerniere per mobili.
NO965395D0 (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
NL7610736A (nl) Werkwijze voor het bereiden van preparaten met antigene activiteit.
NL193781B (nl) Inrichting voor het stabiliseren van seismische energiebronnen.
NL7703877A (nl) Immuno-onderzoek voor de bepaling van catechol- aminen, alsmede voor de uitvoering van een dergelijk onderzoek bruikbare antigenen en antilichamen.
ES264798Y (es) Dispositivo de cierre para cinturones de seguridad.
NL7713784A (nl) Inrichting voor het vervaardigen van monsters voor beproevingen door roentgenfluorescentie.
NL7713952A (nl) Radio-immunologische methode voor het bepalen van de schildklierfunktie door een in vitro onderzoek in bloedserum.
NL182334C (nl) Bevestigingsinrichting voor schuifdeuren, in het bijzonder voor meubels.
NL7708686A (nl) Riemschijf, in het bijzonder voor het aandrij- ven van voertuigaggregaten.
IT215721Z2 (it) Dispositivo di attivazione di cariche accendibili, particolarmente in ambiente subacqueo.
IT7822486A0 (it) Dispositivo di attacco in particolare per cinture disicurezza.